Melanotan 1 vs Melanotan 2 vs PT-141: Melanocortin Peptide Research Comparison 2026

# Melanotan 1 vs Melanotan 2 vs PT-141: Melanocortin Peptide Research Comparison 2026

> Research Use Only Disclaimer: Melanotan I, Melanotan II, and PT-141 are peptides studied in research contexts. Melanotan I (afamelanotide) is FDA-approved as Scenesse® for erythropoietic protoporphyria; PT-141 (bremelanotide) is FDA-approved as Vyleesi® for hypoactive sexual desire disorder. Melanotan II remains a research compound not approved for human therapeutic use. This article is for educational and research purposes only. Not medical advice.

The melanocortin peptide family has generated significant scientific interest for decades. Three compounds stand out in the research literature: Melanotan I (MT-1), Melanotan II (MT-2), and PT-141 (bremelanotide). While all three act on melanocortin receptors (MCRs), they differ dramatically in receptor selectivity, biological effects, clinical evidence, and regulatory status. Understanding these differences is essential for researchers designing studies in pigmentation biology, photoprotection, sexual dysfunction, and metabolic physiology.

---

The Melanocortin Receptor System: Foundation for Comparison

The melanocortin system comprises five G-protein-coupled receptors (MC1R–MC5R) distributed across multiple tissue types. Each receptor mediates distinct physiological functions:

• •MC1R: Primarily expressed in melanocytes; controls pigmentation and UV-protective responses
• •MC2R: Expressed in adrenal cortex; ACTH receptor for cortisol production
• •MC3R: Central nervous system and peripheral tissues; energy homeostasis, inflammation
• •MC4R: Hypothalamus and brainstem; appetite regulation, sexual function, erectile physiology
• •MC5R: Exocrine glands; sebaceous secretion, some thermoregulation

The critical insight is that receptor selectivity — which MCRs a compound binds and how potently — determines the compound's biological profile and side-effect landscape. The three compounds in this comparison differ precisely in this selectivity.

---

Melanotan I (MT-1 / Afamelanotide)

Mechanism and Receptor Profile

Melanotan I is a linear, 13-amino-acid synthetic analog of α-melanocyte-stimulating hormone (α-MSH), the endogenous MC1R ligand. MT-1 demonstrates high selectivity for MC1R compared to other melanocortin receptors, which underlies its utility in photoprotective and pigmentation research.

The peptide promotes eumelanin synthesis in melanocytes via cAMP-mediated signaling, upregulates DNA repair mechanisms (nucleotide excision repair), and has documented anti-inflammatory effects through peripheral MC1R and MC3R pathways. Its linear structure distinguishes it from the cyclic MT-2.

FDA Approval: Scenesse® for EPP

MT-1 achieved regulatory approval in the EU (2014) and USA (2019) as Scenesse® (afamelanotide) for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxicity. The Phase 3 randomized controlled trial by Langendonk et al. (New England Journal of Medicine, 2015; demonstrated that subcutaneous MT-1 implants significantly increased time-to-burn under natural light and improved patient quality of life metrics compared to placebo.

Research Applications

Beyond EPP, MT-1 research encompasses:

• •Photoprotection in normal skin (melanogenesis induction before UV exposure)
• •Vitiligo — melanocyte stimulation at depigmented sites
• •Polymorphous light eruption — immunological photoprotection
• •Melanoma prevention — upregulation of eumelanin (protective pigment) vs. pheomelanin

Side Effect Profile

Given its MC1R selectivity, MT-1 produces fewer systemic effects than MT-2. Research-reported adverse events include nausea (particularly with injection-based formulations), facial flushing, and spontaneous erections in male subjects (via residual MC4R activity). The implant formulation used in EPP trials substantially reduces peak plasma concentrations and associated side effects.

---

Melanotan II (MT-2)

Mechanism and Receptor Profile

Melanotan II is a cyclic heptapeptide (cyclo-[Nle4, D-Phe7]-α-MSH), synthesized to be a more potent and longer-acting analog of α-MSH. The cyclization increases proteolytic stability and shifts the receptor binding profile relative to MT-1.

MT-2 is a non-selective melanocortin agonist, binding MC1R, MC3R, MC4R, and MC5R with varying affinity. This broad receptor engagement drives both its utility as a research tool for studying the complete melanocortin system and its wider side-effect profile compared to MT-1 or PT-141.

Key Research Areas

Pigmentation research: MT-2's potent MC1R agonism produces intense melanogenesis, making it valuable in hypopigmentation research. Tanning response without UV exposure has been extensively documented in preclinical and early clinical studies.

Sexual dysfunction research: MT-2's MC4R agonism produces pro-erectile effects in both male and female animal models. The landmark early studies by Wessells et al. (Journal of Urology, 2000; in human males demonstrated its potential, but development halted due to cardiovascular and other systemic effects. This MC4R activity ultimately led to the development of PT-141.

Appetite suppression: MC4R-mediated central effects of MT-2 reduce food intake in rodent models, overlapping with the mechanisms of MC4R-specific compounds in obesity research.

Metabolic effects: MC3R and MC4R signaling modulates insulin sensitivity and energy expenditure, making MT-2 relevant to metabolic syndrome research.

Side Effect Profile

MT-2's non-selective binding generates a broader adverse event profile than either MT-1 or PT-141:

• •Nausea/vomiting (particularly at higher doses, via area postrema MC receptors)
• •Spontaneous erections (MC4R-mediated; can be prolonged)
• •Facial flushing and hyperpigmentation (diffuse, not site-specific)
• •Yawning (central MC4R effects)
• •Blood pressure fluctuations (reported in some studies)

Because MT-2 is not FDA-approved, its use outside controlled research settings raises significant safety concerns.

---

PT-141 / Bremelanotide

Mechanism and Receptor Profile

PT-141 (bremelanotide) was developed directly from MT-2 research by modifying the structure to improve pharmacokinetic properties and reduce cardiovascular side effects. It is a cyclic heptapeptide that acts as a selective MC4R agonist, with substantially reduced activity at MC1R compared to MT-2.

The MC4R selectivity means PT-141 exerts its primary effects through central nervous system pathways governing sexual motivation and arousal — without the melanogenesis effects of MT-1 or MT-2.

FDA Approval: Vyleesi® for FSIAD

In 2019, the FDA approved bremelanotide as Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) / female sexual interest and arousal disorder (FSIAD) in premenopausal women. This makes PT-141 the first approved non-hormonal, centrally-acting treatment for this indication.

The pivotal clinical trials (RECONNECT studies; Clayton AH et al., Obstetrics & Gynecology, 2016; for the approval package) demonstrated statistically significant improvements in sexual desire and reductions in distress associated with HSDD in premenopausal women.

Research Applications Beyond FSIAD

• •Male erectile dysfunction: MC4R pathways contribute to erectile physiology; PT-141 research in male subjects demonstrates pro-erectile effects independent of vascular mechanisms (relevant for psychogenic or CNS-mediated ED)
• •Central mechanisms of sexual desire: PT-141 has been used as a pharmacological probe in neuroimaging research to delineate hypothalamic circuits governing sexual motivation
• •Potentially additive to PDE5 inhibitors: Some researchers have investigated whether MC4R activation and PDE5 inhibition (sildenafil, tadalafil) have complementary mechanisms

Side Effect Profile

PT-141's main adverse effects reflect its MC4R activity and formulation (intranasal or subcutaneous):

• •Nausea (most common; managed with ondansetron pretreatment in trials)
• •Flushing and hyperpigmentation at injection sites (residual MC1R activity)
• •Transient blood pressure elevation (dose-dependent; significant concern vs. MT-2 development)
• •Headache

The intranasal formulation used in earlier research was discontinued due to blood pressure concerns; the approved Vyleesi® uses subcutaneous injection with a 1.75 mg dose and specific cardiovascular contraindications.

---

Head-to-Head Comparison Table

---

Selecting the Right Compound for Research Purposes

When MT-1 Is the Appropriate Research Tool

Melanotan I is the compound of choice for studies requiring:

• •MC1R-specific investigations without confounding MC4R effects
• •Photoprotection mechanisms — particularly nucleotide excision repair upregulation
• •EPP model studies — the approved indication with established safety data
• •Pigmentation biology where sexual/erectile effects would confound results

The established clinical literature and available pharmacokinetic data from the Phase 3 EPP trials make MT-1 the best-characterized compound in this trio.

When MT-2 Is the Appropriate Research Tool

Melanotan II serves as a non-selective melanocortin probe for:

• •Broad MCR pharmacology — studying the complete melanocortin system simultaneously
• •Comparative melanocortin physiology — using MT-2 with receptor-selective antagonists (SHU9119, etc.) to dissect contributions of individual MCRs
• •Metabolic/feeding behavior research where pan-MCR stimulation is scientifically appropriate

Given its non-approved status and broader side-effect profile, MT-2 requires careful dosing protocols and ethical oversight.

When PT-141 Is the Appropriate Research Tool

Bremelanotide is optimal for:

• •MC4R-specific sexual physiology studies
• •Central mechanisms of sexual desire research
• •Psychogenic erectile dysfunction models
• •Combination studies with other sexual health compounds

Its FDA-approved status means human research has an established safety baseline, though the specific FSIAD indication requires appropriate IRB protocols.

---

Stacking and Combination Research

Researchers have explored combinations within this class:

MT-1 + UV protocols: MT-1 priming before UV exposure enhances photoprotective melanogenesis; the two stimuli act synergistically at MC1R.

PT-141 + PDE5 inhibitors: MC4R (central) and PDE5 inhibition (peripheral vascular) represent complementary mechanisms for erectile function, with some clinical researchers reporting additive benefit in difficult-to-treat cases.

MT-2 as mechanistic probe: Using MT-2 alongside selective MCR antagonists (e.g., SHU9119 for MC3R/MC4R blockade) allows researchers to attribute observed effects to specific receptor subtypes.

---

Regulatory and Sourcing Considerations

Melanotan I (Afamelanotide / Scenesse®): Available as FDA-approved therapy through licensed prescribers for EPP. Research-grade material available through licensed peptide suppliers with appropriate IRB protocols.

Melanotan II: Not approved for any therapeutic use. Available as a research-use-only (RUO) compound from licensed research peptide suppliers. Purchase requires declaration of research intent and compliance with applicable regulations.

PT-141 (Bremelanotide / Vyleesi®): FDA-approved; available by prescription. Research-grade bremelanotide available through licensed research suppliers for non-human and appropriately supervised human research.

Researchers should consult Peptides.SO's supplier listings for verified, third-party-tested melanocortin peptides and review site-specific RUO policies.

---

Internal Resources

• •Melanotan I (Afamelanotide) Research Profile
• •Melanotan II Research Profile
• •PT-141 (Bremelanotide) Research Profile
• •PT-141 vs Kisspeptin: Sexual Health Comparison
• •Melanotan I vs Melanotan II: Tanning Research Comparison

---

Conclusion

The three melanocortin research peptides occupy distinct scientific niches. MT-1 is the gold standard for photoprotection and MC1R-specific research, with the strongest clinical evidence base validated through EPP approval. MT-2 serves as a broad pharmacological probe for the full melanocortin system but carries the highest systemic side-effect burden. PT-141 is the most refined compound for MC4R-mediated sexual physiology, with FDA approval anchoring its clinical evidence base in FSIAD.

For researchers, the choice depends fundamentally on which receptor pathway and biological outcome is the subject of investigation. All three compounds are available for appropriately supervised research through licensed suppliers — consult the individual research profiles and supplier listings on Peptides.SO for sourcing guidance.

---

For research purposes only. Not for human use outside approved clinical indications. Always consult applicable regulations before initiating peptide research protocols.